Microbiome as a tool and a target in the effort to address antimicrobial resistance

Proceedings of the National Academy of Sciences of the United States of America

Volumn 115, Issue 51, 2018, Pages 12902-12910

  Relman, David A ^a,b   Lipsitch, Marc ^c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Antibacterial agents; Drug resistance; Horizontal gene transfer; Immune system; Microbiota

Indexed keywords

ANTIBIOTIC AGENT; BACTERIAL VACCINE; ANTIINFECTIVE AGENT; VACCINE;

ANTIBIOTIC RESISTANCE; BACTERIAL CELL WALL; BACTERIAL COLONIZATION; BACTERIAL GENE; BACTERIAL INFECTION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DENDRITIC CELL; DRUG EFFECT; DRUG EXPOSURE; GENE TARGETING; HOST PATHOGEN INTERACTION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFECTION PREVENTION; LYMPHOCYTE DIFFERENTIATION; MICROBIOME; NONHUMAN; PRIORITY JOURNAL; REVIEW; COMMUNICABLE DISEASE; COMMUNICABLE DISEASE CONTROL; GENETICS; IMMUNOLOGY; MICROFLORA; PROCEDURES;

ANTI-INFECTIVE AGENTS; COMMUNICABLE DISEASE CONTROL; COMMUNICABLE DISEASES; DRUG RESISTANCE, MICROBIAL; HOST MICROBIAL INTERACTIONS; HUMANS; MICROBIOTA; VACCINES;

EID: 85058617910     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1717163115     Document Type: Review

References (124)

1. Hooper LV, Littman DR, Macpherson AJ (2012) Interactions between the microbiota and the immune system. Science 336:1268–1273.
2. Chung H, et al. (2012) Gut immune maturation depends on colonization with a host-specific microbiota. Cell 149:1578–1593.
3. Atarashi K, et al. (2011) Induction of colonic regulatory T cells by indigenous Clostridium species. Science 331:337–341.
4. Atarashi K, et al. (2013) Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota. Nature 500:232–236.
5. Ivanov II, et al. (2009) Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 139:485–498.
6. Round JL, Palm NW (2018) Causal effects of the microbiota on immune-mediated diseases. Sci Immunol 3:eaao1603.
7. Olszak T, et al. (2012) Microbial exposure during early life has persistent effects on natural killer T cell function. Science 336:489–493.
8. Gensollen T, Iyer SS, Kasper DL, Blumberg RS (2016) How colonization by microbiota in early life shapes the immune system. Science 352:539–544.
9. Gomez de Agüero M, et al. (2016) The maternal microbiota drives early postnatal innate immune development. Science 351:1296–1302.
10. Macpherson AJ, et al. (2000) A primitive T cell-independent mechanism of intestinal mucosal IgA responses to commensal bacteria. Science 288:2222–2226.
11. Cerutti A, Rescigno M (2008) The biology of intestinal immunoglobulin A responses. Immunity 28:740–750.
12. Bunker JJ, et al. (2015) Innate and adaptive humoral responses coat distinct commensal bacteria with immunoglobulin A. Immunity 43:541–553.
13. Planer JD, et al. (2016) Development of the gut microbiota and mucosal IgA responses in twins and gnotobiotic mice. Nature 534:263–266.
14. Wu W, et al. (2017) Microbiota metabolite short-chain fatty acid acetate promotes intestinal IgA response to microbiota which is mediated by GPR43. Mucosal Immunol 10:946–956.
15. White CA, et al. (2014) Histone deacetylase inhibitors upregulate B cell microRNAs that silence AID and Blimp-1 expression for epigenetic modulation of antibody and autoantibody responses. J Immunol 193:5933–5950.
16. Koch MA, et al. (2016) Maternal IgG and IgA antibodies dampen mucosal T helper cell responses in early life. Cell 165:827–841.
17. Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, Edberg S, Medzhitov R (2004) Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 118:229–241.
18. Pasare C, Medzhitov R (2005) Control of B-cell responses by Toll-like receptors. Nature 438:364–368.
19. McSorley SJ, Ehst BD, Yu Y, Gewirtz AT (2002) Bacterial flagellin is an effective adjuvant for CD4+ T cells in vivo. J Immunol 169:3914–3919.
20. + regulatory T-cell development by a commensal bacterium of the intestinal microbiota. Proc Natl Acad Sci USA 107:12204–12209.
21. Mazmanian SK, Liu CH, Tzianabos AO, Kasper DL (2005) An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell 122:107–118.
22. Shibata N, Kunisawa J, Kiyono H (2017) Dietary and microbial metabolites in the regulation of host immunity. Front Microbiol 8:2171.
23. Zelante T, et al. (2013) Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22. Immunity 39:372–385.
24. Raqib R, et al. (2006) Improved outcome in shigellosis associated with butyrate induction of an endogenous peptide antibiotic. Proc Natl Acad Sci USA 103:9178–9183.
25. Singh N, et al. (2014) Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis. Immunity 40:128–139.
26. Macia L, et al. (2015) Metabolite-sensing receptors GPR43 and GPR109A facilitate dietary fibre-induced gut homeostasis through regulation of the inflammasome. Nat Commun 6:6734.
27. Smith PM, et al. (2013) The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science 341:569–573.
28. Furusawa Y, et al. (2013) Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 504:446–450.
29. Chang PV, Hao L, Offermanns S, Medzhitov R (2014) The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition. Proc Natl Acad Sci USA 111:2247–2252.
30. Arrieta MC, et al.; CHILD Study Investigators (2015) Early infancy microbial and metabolic alterations affect risk of childhood asthma. Sci Transl Med 7:307ra152.
31. Mitre E, et al. (2018) Association between use of acid-suppressive medications and antibiotics during infancy and allergic diseases in early childhood. JAMA Pediatr 172:e180315.
32. Levy M, Kolodziejczyk AA, Thaiss CA, Elinav E (2017) Dysbiosis and the immune system. Nat Rev Immunol 17:219–232.
33. Benoun JM, Labuda JC, McSorley SJ (2016) Collateral damage: Detrimental effect of antibiotics on the development of protective immune memory. MBio 7:e01520-16.
34. Oh JZ, et al. (2014) TLR5-mediated sensing of gut microbiota is necessary for antibody responses to seasonal influenza vaccination. Immunity 41:478–492.
35. D’Costa VM, et al. (2011) Antibiotic resistance is ancient. Nature 477:457–461.
36. Lugli GA, et al. (2017) Ancient bacteria of the Ötzi’s microbiome: A genomic tale from the Copper Age. Microbiome 5:5, and erratum (2017) 5:23.
37. Clemente JC, et al. (2015) The microbiome of uncontacted Amerindians. Sci Adv 1:e1500183.
38. Smits SA, et al. (2017) Seasonal cycling in the gut microbiome of the Hadza hunter-gatherers of Tanzania. Science 357:802–806.
39. Sommer MOA, Dantas G, Church GM (2009) Functional characterization of the antibiotic resistance reservoir in the human microflora. Science 325:1128–1131.
40. Forslund K, et al. (2013) Country-specific antibiotic use practices impact the human gut resistome. Genome Res 23:1163–1169.
41. Hu Y, et al. (2013) Metagenome-wide analysis of antibiotic resistance genes in a large cohort of human gut microbiota. Nat Commun 4:2151.
42. Yang Z, et al. (2016) Preliminary analysis showed country-specific gut resistome based on 1,267 feces samples. Gene 581:178–182.
43. Ravi A, et al. (2015) The commensal infant gut meta-mobilome as a potential reservoir for persistent multidrug resistance integrons. Sci Rep 5:15317.
44. Dethlefsen L, Huse S, Sogin ML, Relman DA (2008) The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biol 6:e280.
45. Dethlefsen L, Relman DA (2011) Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc Natl Acad Sci USA 108:4554–4561.
46. Paine RT, Tegner MJ, Johnson EA (1998) Compounded perturbations yield ecological surprises. Ecosystems 1:535–545.
47. Zaura E, et al. (2015) Same exposure but two radically different responses to antibiotics: Resilience of the salivary microbiome versus long-term microbial shifts in feces. MBio 6:e01693-15.
48. Raymond F, et al. (2016) The initial state of the human gut microbiome determines its reshaping by antibiotics. ISME J 10:707–720.
49. Nogacka A, et al. (2017) Impact of intrapartum antimicrobial prophylaxis upon the intestinal microbiota and the prevalence of antibiotic resistance genes in vaginally delivered full-term neonates. Microbiome 5:93.
50. Korpela K, et al. (2016) Intestinal microbiome is related to lifetime antibiotic use in Finnish pre-school children. Nat Commun 7:10410.
51. Gibson MK, et al. (2016) Developmental dynamics of the preterm infant gut microbiota and antibiotic resistome. Nat Microbiol 1:16024.
52. Yassour M, et al.; DIABIMMUNE Study Group (2016) Natural history of the infant gut microbiome and impact of antibiotic treatment on bacterial strain diversity and stability. Sci Transl Med 8:343ra81.
53. Lu N, et al. (2014) DNA microarray analysis reveals that antibiotic resistance-gene diversity in human gut microbiota is age related. Sci Rep 4:4302.
54. Falkow S, Wohlhieter JA, Citarella RV, Baron LS (1964) Transfer of episomic elements to Proteus. I. Transfer of F-linked chromosomal determinants. J Bacteriol 87:209–219.
55. Falkow S, Wohlhieter JA, Citarella RV, Baron LS (1964) Transfer of episomic elements to Proteus. II. Nature of Lac+ Proteus strains isolated from clinical specimens. J Bacteriol 88:1598–1601.
56. Falkow S, Citarella RV, Wohlhieter JA (1966) The molecular nature of R-factors. J Mol Biol 17:102–116.
57. Shoemaker NB, Vlamakis H, Hayes K, Salyers AA (2001) Evidence for extensive resistance gene transfer among Bacteroides spp. and among Bacteroides and other genera in the human colon. Appl Environ Microbiol 67:561–568.
58. Smillie CS, et al. (2011) Ecology drives a global network of gene exchange connecting the human microbiome. Nature 480:241–244.
59. Pehrsson EC, et al. (2016) Interconnected microbiomes and resistomes in low-income human habitats. Nature 533:212–216.
60. Kuss SK, et al. (2011) Intestinal microbiota promote enteric virus replication and systemic pathogenesis. Science 334:249–252.
61. Parker EPK, et al. (2018) Influence of the intestinal microbiota on the immunogenicity of oral rotavirus vaccine given to infants in south India. Vaccine 36:264–272.
62. Harris V, et al. (2018) Rotavirus vaccine response correlates with the infant gut microbiota composition in Pakistan. Gut Microbes 9:93–101.
63. Harris VC, et al. (2017) Significant correlation between the infant gut microbiome and rotavirus vaccine response in rural Ghana. J Infect Dis 215:34–41.
64. Valdez Y, Brown EM, Finlay BB (2014) Influence of the microbiota on vaccine effectiveness. Trends Immunol 35:526–537.
65. Zimmermann P, Curtis N (2018) The influence of probiotics on vaccine responses–A systematic review. Vaccine 36:207–213.
66. Nothaft H, et al. (2017) Co-administration of the Campylobacter jejuni N-glycan based vaccine with probiotics improves vaccine performance in broiler chickens. Appl Environ Microbiol AEM.01523-17.
67. Lazarus RP, et al. (2018) The effect of probiotics and zinc supplementation on the immune response to oral rotavirus vaccine: A randomized, factorial design, placebo-controlled study among Indian infants. Vaccine 36:273–279.
68. Praharaj I, John SM, Bandyopadhyay R, Kang G (2015) Probiotics, antibiotics and the immune responses to vaccines. Philos Trans R Soc Lond B Biol Sci 370:20140144.
69. Maltezou HC, et al. (2013) Impact of postpartum influenza vaccination of mothers and household contacts in preventing febrile episodes, influenza-like illness, healthcare seeking, and administration of antibiotics in young infants during the 2012-2013 influenza season. Clin Infect Dis 57:1520–1526.
70. Norhayati MN, Ho JJ, Azman MY (2017) Influenza vaccines for preventing acute otitis media in infants and children. Cochrane Database Syst Rev 10:CD010089.
71. Kash JC, Taubenberger JK (2015) The role of viral, host, and secondary bacterial factors in influenza pathogenesis. Am J Pathol 185:1528–1536.
72. Malhotra-Kumar S, et al.; GRACE study group (2016) Impact of amoxicillin therapy on resistance selection in patients with community-acquired lower respiratory tract infections: A randomized, placebo-controlled study. J Antimicrob Chemother 71:3258–3267.
73. Lipsitch M (2001) Measuring and interpreting associations between antibiotic use and penicillin resistance in Streptococcus pneumoniae. Clin Infect Dis 32:1044–1054.
74. Coles CL, et al. (2013) Mass distribution of azithromycin for trachoma control is associated with increased risk of azithromycin-resistant Streptococcus pneumoniae carriage in young children 6 months after treatment. Clin Infect Dis 56:1519–1526.
75. Barbosa-Cesnik C, et al. (2006) Predictors for Haemophilus influenzae colonization, antibiotic resistance and for sharing an identical isolate among children attending 16 licensed day-care centers in Michigan. Pediatr Infect Dis J 25:219–223.
76. Koningstein M, et al. (2015) Prevalence and risk factors for colonization with extended-spectrum cephalosporin-resistant Escherichia coli in children attending daycare centers: A cohort study in The Netherlands. J Pediatric Infect Dis Soc 4:e93–e99.
77. Lekkerkerk WSN, et al. (2017) Newly identified risk factors for MRSA carriage in The Netherlands. PLoS One 12:e0188502.
78. Høiby N, et al. (1997) Excretion of ciprofloxacin in sweat and multiresistant Staphylococcus epidermidis. Lancet 349:167–169.
79. Wind CM, et al. (2017) Decreased azithromycin susceptibility of Neisseria gonorrhoeae isolates in patients recently treated with azithromycin. Clin Infect Dis 65:37–45.
80. Brinkac L, Voorhies A, Gomez A, Nelson KE (2017) The threat of antimicrobial resistance on the human microbiome. Microb Ecol 74:1001–1008.
81. Bogaert D, De Groot R, Hermans PW (2004) Streptococcus pneumoniae colonisation: The key to pneumococcal disease. Lancet Infect Dis 4:144–154.
82. Tuazon CU (1984) Skin and skin structure infections in the patient at risk: Carrier state of Staphylococcus aureus. Am J Med 76:166–171.
83. Viau R, et al. (2016) Intestinal carriage of carbapenemase-producing organisms: Current status of surveillance methods. Clin Microbiol Rev 29:1–27.
84. Lipsitch M, O’Hagan JJ (2007) Patterns of antigenic diversity and the mechanisms that maintain them. J R Soc Interface 4:787–802.
85. Lee GM, et al. (2017) Immunization, antibiotic use, and pneumococcal colonization over a 15-year period. Pediatrics 140:e20170001.
86. Flasche S, et al. (2011) Effect of pneumococcal conjugate vaccination on serotype-specific carriage and invasive disease in England: A cross-sectional study. PLoS Med 8:e1001017.
87. McCormick AW, et al. (2003) Geographic diversity and temporal trends of antimicrobial resistance in Streptococcus pneumoniae in the United States. Nat Med 9:424–430.
88. Feikin DR, et al.; Serotype Replacement Study Group (2013) Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: A pooled analysis of multiple surveillance sites. PLoS Med 10:e1001517.
89. Lehtinen S, et al. (2017) Evolution of antibiotic resistance is linked to any genetic mechanism affecting bacterial duration of carriage. Proc Natl Acad Sci USA 114:1075–1080.
90. Kyaw MH, et al.; Active Bacterial Core Surveillance of the Emerging Infections Program Network (2006) Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med 354:1455–1463.
91. Ubukata K, et al.; Invasive Pneumococcal Diseases Surveillance Study Group (2015) Serotype changes and drug resistance in invasive pneumococcal diseases in adults after vaccinations in children, Japan, 2010-2013. Emerg Infect Dis 21:1956–1965.
92. Desai AP, et al. (2015) Decline in pneumococcal nasopharyngeal carriage of vaccine serotypes after the introduction of the 13-valent pneumococcal conjugate vaccine in children in Atlanta, Georgia. Pediatr Infect Dis J 34:1168–1174.
93. Joice R, Lipsitch M (2013) Targeting imperfect vaccines against drug-resistance determinants: A strategy for countering the rise of drug resistance. PLoS One 8:e68940.
94. Tekle YI, et al. (2012) Controlling antimicrobial resistance through targeted, vaccine-induced replacement of strains. PLoS One 7:e50688.
95. Masala GL, Lipsitch M, Bottomley C, Flasche S (2017) Exploring the role of competition induced by non-vaccine serotypes for herd protection following pneumococcal vaccination. J R Soc Interface 14:20170620.
96. Lewnard JA, Givon-Lavi N, Weinberger DM, Lipsitch M, Dagan R (2017) Pan-serotype reduction in progression of Streptococcus pneumoniae to otitis media after rollout of pneumococcal conjugate vaccines. Clin Infect Dis 65:1853–1861.
97. Dagan R, Pelton S, Bakaletz L, Cohen R (2016) Prevention of early episodes of otitis media by pneumococcal vaccines might reduce progression to complex disease. Lancet Infect Dis 16:480–492.
98. Mika M, et al. (2017) Influence of the pneumococcal conjugate vaccines on the temporal variation of pneumococcal carriage and the nasal microbiota in healthy infants: A longitudinal analysis of a case-control study. Microbiome 5:85.
99. Biesbroek G, et al. (2014) Seven-valent pneumococcal conjugate vaccine and nasopharyngeal microbiota in healthy children. Emerg Infect Dis 20:201–210.
100. Ang L, et al. (2014) The establishment of the infant intestinal microbiome is not affected by rotavirus vaccination. Sci Rep 4:7417.
101. García-López R, Pérez-Brocal V, Diez-Domingo J, Moya A (2012) Gut microbiota in children vaccinated with rotavirus vaccine. Pediatr Infect Dis J 31:1300–1302.
102. Centers for Disease Control and Prevention (2013) Antibiotic resistant threats in the United States, 2013. Available at https://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf. Accessed October 23, 2018.
103. Knisely JM, Liu B, Ranallo RT, Zou L (2016) Vaccines for healthcare-associated infections: Promise and challenge. Clin Infect Dis 63:657–662.
104. Lynn DJ, Pulendran B (2018) The potential of the microbiota to influence vaccine responses. J Leukoc Biol 103:225–231.
105. Littman DR (2018) Do the microbiota influence vaccines and protective immunity to pathogens? If so, is there potential for efficacious microbiota-based vaccines? Cold Spring Harb Perspect Biol 10:a029355.
106. Macpherson AJ (2018) Do the microbiota influence vaccines and protective immunity to pathogens? Issues of sovereignty, federalism, and points-testing in the prokaryotic and eukaryotic spaces of the host-microbial superorganism. Cold Spring Harb Perspect Biol 10:a029363.
107. Donia MS, et al. (2014) A systematic analysis of biosynthetic gene clusters in the human microbiome reveals a common family of antibiotics. Cell 158:1402–1414.
108. Zipperer A, et al. (2016) Human commensals producing a novel antibiotic impair pathogen colonization. Nature 535:511–516.
109. Bikard D, Barrangou R (2017) Using CRISPR-Cas systems as antimicrobials. Curr Opin Microbiol 37:155–160.
110. Ouwehand AC, Forssten S, Hibberd AA, Lyra A, Stahl B (2016) Probiotic approach to prevent antibiotic resistance. Ann Med 48:246–255.
111. Singh R, et al. (2014) Donor feces infusion for eradication of extended spectrum beta-lactamase producing Escherichia coli in a patient with end stage renal disease. Clin Microbiol Infect 20:O977–O978.
112. Crum-Cianflone NF, Sullivan E, Ballon-Landa G (2015) Fecal microbiota transplantation and successful resolution of multidrug-resistant-organism colonization. J Clin Microbiol 53:1986–1989.
113. Millan B, et al. (2016) Fecal microbial transplants reduce antibiotic-resistant genes in patients with recurrent Clostridium difficile infection. Clin Infect Dis 62:1479–1486.
114. Halpin AL, McDonald LC (2016) Editorial commentary: The dawning of microbiome remediation for addressing antibiotic resistance. Clin Infect Dis 62:1487–1488.
115. Jouhten H, Mattila E, Arkkila P, Satokari R (2016) Reduction of antibiotic resistance genes in intestinal microbiota of patients with recurrent Clostridium difficile infection after fecal microbiota transplantation. Clin Infect Dis 63:710–711.
116. Smillie CS, et al. (2018) Strain tracking reveals the determinants of bacterial engraftment in the human gut following fecal microbiota transplantation. Cell Host Microbe 23:229–240.e5.
117. Davido B, et al. (2017) Is faecal microbiota transplantation an option to eradicate highly drug-resistant enteric bacteria carriage? J Hosp Infect 95:433–437.
118. Kraft CS (2016) FMT for MDRO Colonization after infection in renal transplant recipients. NCT02922816. Available at https://ClinicalTrials.gov/show/NCT02922816. Accessed April 16, 2018.
119. Dubberke E (2014) FMT for multi-drug resistant organism reversal. NCT02312986. Available at https://ClinicalTrials.gov/show/NCT02312986. Accessed April 16, 2018.
120. Pamer EG (2016) Resurrecting the intestinal microbiota to combat antibiotic-resistant pathogens. Science 352:535–538.
121. Bäumler AJ, Sperandio V (2016) Interactions between the microbiota and pathogenic bacteria in the gut. Nature 535:85–93.
122. Olsan EE, et al. (2017) Colonization resistance: The deconvolution of a complex trait. J Biol Chem 292:8577–8581.
123. Wu G, et al. (2016) Diminution of the gut resistome after a gut microbiota-targeted dietary intervention in obese children. Sci Rep 6:24030.
124. Lederberg J (2000) Infectious history. Science 288:287–293.